PrecisemAb Biotech Co., Ltd.

11:00 AM - 12:00 PM (PDT), Tuesday, June 14, 2022
We are PrecisemAb, a company that is committed to blocking side effects caused by antibody therapy. Our disease-directed Universal Antibody Lock is an autologous masking structure on the binding site of an antibody that allows antibody drugs to take effect only in diseased areas. This makes antibody treatment extraordinarily safe.

Compared to competitors, our Antibody Lock
1) is the 1st antibody lock that uses the antibody's own structure as a masking domain.
2) has higher masking ability and can fully activate the antibody when in the diseased areas.
3) has low immunogenicity and non-anti-idiotypic antibody binding, which prolongs serum half-life and leads to higher therapeutic efficacy.
4) takes only 3 months for Lock-design and function test.

We have successfully applied the technology to autoimmune diseases (TNFα and IL-1b) and immuno-oncology therapy (CTLA4, PD-1, 4-1BB). Potential application to ADC drugs is now under lead optimization. Through providing a customized lock-design service and co-developing lock-antibody drugs with pharma, PrecisemAb is dedicated to creating the safest antibody therapy for patients.
Speaker
photo
CEO
PrecisemAb Biotech Co., Ltd.